- Hyatt Hotels Corp (NYSE:H) reported third-quarter FY22 sales of $1.54 billion, beating the consensus of $1.45 billion.
- Comparable system-wide RevPAR increased 45.9% to $133.31. System-wide Net Rooms Growth was 18.7%.
- Comparable owned and leased hotels RevPAR increased 47.4% to $177.24.
- The company held $1.4 billion in cash and equivalents as of September 30, 2022.
- Adjusted EBITDA rose to $252 million versus $110 million last year.
- Adjusted EPS of $0.64 beat the analyst consensus of $0.28.
- Hyatt repurchased 1.87 million shares for $162 million in Q3.
- At the end of Q3, the company had a consolidated debt of $3.8 billion.
- Outlook: Hyatt expects FY22 capital expenditure to be $210 million.
- The company currently expects to grow net rooms by approximately 6.5%.
- It expects system-wide constant dollar RevPAR to grow 60% – 65% from 2021.
- Price Action: H shares are trading lower by 0.39% at $91.61 in premarket on the last check Thursday.
- Photo Via Company
Alpine Immune Sciences Priced ~13.6M Share Public Offering of Common Stock @$7.35/Share
Alpine Immune Sciences, Inc. (Nasdaq: ALPN) announced the pricing of its underwritten public offering of 13,606,000 shares of its common stock pursuant to its existing shelf registration statement. The shares of common stock are being offered at a public offering price of $7.35 per share.
